The Severe Von Willebrand Disease (sVWD) Patient Registry

VWD - Von Willebrand's Disease Clinical Trial

Official title:

The Severe Von Willebrand Disease Patient Registry: A Longitudinal Natural History and Patient Outcomes Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05437536
• Other study ID #: VWD-001
• Status: Recruiting
• Start date: December 10, 2021
• Est. completion date: January 2027

Study information

• Verified date: April 2024
• Source: VWD Connect Foundation
• Contact: Christina Morgenthaler, MS, MBA
• Phone: (279) 346-6202
• Email: morgenthaler[@]vwdregistry.org
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

A web-based registry will be created by the sponsor, VWD Connect Foundation (VCF), to collect data on patients with severe Von Willebrand Disease (sVWD). Data will be self-reported by patients and/or collected by registry personnel, as appropriate. The purpose of the sVWD Patient Registry is to create a database of well-characterized (with respect to demographics, medical history, symptoms, laboratory and genetic data, etc.) patients with sVWD for participation in retrospective and prospective research.

Description:

A web-based registry will be created by the sponsor, VWD Connect Foundation (VCF), to collect data on patients with severe Von Willebrand Disease (sVWD). The initial launch of the registry will be limited to patients residing in the United States; however, the registry may be extended to other regions and countries upon the applicable regulatory approvals. Data will be self-reported by patients and/or collected by registry personnel, as appropriate. The purpose of the sVWD Patient Registry is to create a database of well-characterized (with respect to demographics, medical history, symptoms, laboratory and genetic data, etc.) patients with sVWD for participation in retrospective and prospective research. Patients who meet all eligibility criteria will be able to participate. Patients will be required to read and sign an Institutional Review Board (IRB)-approved informed consent form prior to any registry-specific activity taking place.

At the time of informed consent, participants will be asked to indicate if they are interested in being contacted by registry personnel for potential participation in future clinical trials and/or studies. Participants who opt out will not be contacted for future studies.

No clinical procedures, testing, or diagnostics will be required by virtue of registry participation. Participants will enter relevant data into a web-based registry portal at regular intervals.

Participants will be asked to complete questionnaires related to their sVWD (including diagnosis, symptoms, treatments, family history, quality of life, etc.) at the time of enrollment and at regular follow up intervals. Questionnaires will be released into the registry in phases as modules for participant completion. The first phase (ie, registry launch) will include, at minimum, modules on demographics, medical history, and concomitant medications. Additionally, the Self-Administered Bleeding Assessment Tool (Self-BAT) will be completed by participants at baseline and regular intervals. Questionnaire modules and the Self-BAT may also be administered in person by qualified registry personnel (e.g., at annual VCF conferences). Laboratory and genetic sequencing data will be provided by the participant, if available. Participants who have not completed a questionnaire in the registry website within a 12-month period will be contacted by registry personnel for follow-up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: January 2027
• Est. primary completion date: January 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Have a clinical diagnosis of Von Willebrand Disease (VWD) with any Von Willebrand factor level(s) < 20%

• Provide informed consent by participant or legally authorized representative

• Be willing and able to comply with study procedures and data collection

• Reside in the United States

NOTE: For inclusion criterion 1, it is not expected that participants will submit evidence of clinical diagnosis at screening; a participant's own confirmation that they have severe VWD will be sufficient for meeting the enrollment requirement and obtaining access to the registry. Laboratory values will be provided during the conduct of the study, and participants with Von Willebrand factor levels > 20% may be excluded from data analysis on a case-by-case basis in consultation with a subcommittee of the VWD Connect Foundation Medical and Scientific Advisory Board.

Exclusion Criteria:

• Have a clinical diagnosis of acquired VWD

Related Conditions & MeSH terms

• Von Willebrand Diseases
• VWD - Von Willebrand's Disease

Locations

Country	Name	City	State
United States	VWD Connect Foundation	Wellington	Florida

Sponsors (1)

Lead Sponsor	Collaborator
VWD Connect Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Outcomes are not applicable; this study is a patient registry.	Statistical analyses will focus on simple characterization of the registry.	At least 5 years